Valneva on Monday said it reached an agreement in principle with the UK government to supply up to 100 million doses of its vaccine candidate, which will be produced in Scotland. An inactivated whole virus vaccine, the candidate uses the same platform as Ixiaro, Valneva’s FDA-approved vaccine for protection against Japanese encephalitis.

Under the deal, the UK government is expected to help fund clinical studies, and the partners are discussing funding for an expansion to Valneva’s site in Scotland, the biotech says. For its part, Valneva plans investments at its Scottish site and another factory in Sweden. Source: Fierce Pharma 20/7/2020